RU2020105058A - Аналоги 1,2-дигидро-3н-пиразоло[3,4-d]пиримидин-3-она - Google Patents
Аналоги 1,2-дигидро-3н-пиразоло[3,4-d]пиримидин-3-она Download PDFInfo
- Publication number
- RU2020105058A RU2020105058A RU2020105058A RU2020105058A RU2020105058A RU 2020105058 A RU2020105058 A RU 2020105058A RU 2020105058 A RU2020105058 A RU 2020105058A RU 2020105058 A RU2020105058 A RU 2020105058A RU 2020105058 A RU2020105058 A RU 2020105058A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- optionally substituted
- alkyl
- unsubstituted
- group
- Prior art date
Links
- JTNQNHQPENYUGB-UHFFFAOYSA-N 1,2-dihydropyrazolo[3,4-d]pyrimidin-3-one Chemical class C1=NC=C2C(O)=NNC2=N1 JTNQNHQPENYUGB-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims 48
- 125000000217 alkyl group Chemical group 0.000 claims 40
- 201000011510 cancer Diseases 0.000 claims 39
- 150000001875 compounds Chemical class 0.000 claims 38
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 16
- 201000010881 cervical cancer Diseases 0.000 claims 16
- 208000000649 small cell carcinoma Diseases 0.000 claims 16
- 206010008342 Cervix carcinoma Diseases 0.000 claims 15
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 12
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 206010046766 uterine cancer Diseases 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical group 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 206010000830 Acute leukaemia Diseases 0.000 claims 8
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 8
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 8
- 206010004593 Bile duct cancer Diseases 0.000 claims 8
- 208000003174 Brain Neoplasms Diseases 0.000 claims 8
- 206010006187 Breast cancer Diseases 0.000 claims 8
- 208000026310 Breast neoplasm Diseases 0.000 claims 8
- 208000006332 Choriocarcinoma Diseases 0.000 claims 8
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 8
- 206010009944 Colon cancer Diseases 0.000 claims 8
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 8
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 8
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 8
- 208000017604 Hodgkin disease Diseases 0.000 claims 8
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 8
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 8
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 8
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 8
- 208000034578 Multiple myelomas Diseases 0.000 claims 8
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 8
- 206010029260 Neuroblastoma Diseases 0.000 claims 8
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 8
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 8
- 206010033128 Ovarian cancer Diseases 0.000 claims 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 8
- 208000002471 Penile Neoplasms Diseases 0.000 claims 8
- 206010034299 Penile cancer Diseases 0.000 claims 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 8
- 206010060862 Prostate cancer Diseases 0.000 claims 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 8
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 8
- 208000000453 Skin Neoplasms Diseases 0.000 claims 8
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 8
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 8
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 8
- 206010057644 Testis cancer Diseases 0.000 claims 8
- 208000008383 Wilms tumor Diseases 0.000 claims 8
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 8
- 208000026900 bile duct neoplasm Diseases 0.000 claims 8
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 8
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 8
- 208000029742 colonic neoplasm Diseases 0.000 claims 8
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 8
- 201000004101 esophageal cancer Diseases 0.000 claims 8
- 230000001605 fetal effect Effects 0.000 claims 8
- 210000000232 gallbladder Anatomy 0.000 claims 8
- 201000010175 gallbladder cancer Diseases 0.000 claims 8
- 206010017758 gastric cancer Diseases 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 201000007270 liver cancer Diseases 0.000 claims 8
- 208000014018 liver neoplasm Diseases 0.000 claims 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 8
- 201000001441 melanoma Diseases 0.000 claims 8
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 8
- 201000008026 nephroblastoma Diseases 0.000 claims 8
- 201000008968 osteosarcoma Diseases 0.000 claims 8
- 201000002528 pancreatic cancer Diseases 0.000 claims 8
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 8
- 208000037244 polycythemia vera Diseases 0.000 claims 8
- 206010038038 rectal cancer Diseases 0.000 claims 8
- 201000001275 rectum cancer Diseases 0.000 claims 8
- 201000000849 skin cancer Diseases 0.000 claims 8
- 201000011549 stomach cancer Diseases 0.000 claims 8
- 201000003120 testicular cancer Diseases 0.000 claims 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 7
- 206010005003 Bladder cancer Diseases 0.000 claims 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 7
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 7
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 7
- -1 cyano, amino Chemical group 0.000 claims 7
- 210000000244 kidney pelvis Anatomy 0.000 claims 7
- 201000005202 lung cancer Diseases 0.000 claims 7
- 208000020816 lung neoplasm Diseases 0.000 claims 7
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 claims 7
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims 7
- 201000002510 thyroid cancer Diseases 0.000 claims 7
- 201000005112 urinary bladder cancer Diseases 0.000 claims 7
- 206010025323 Lymphomas Diseases 0.000 claims 6
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims 6
- 206010046392 Ureteric cancer Diseases 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 201000011294 ureter cancer Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 150000003973 alkyl amines Chemical class 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000003211 malignant effect Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 3
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 101000621390 Homo sapiens Wee1-like protein kinase Proteins 0.000 claims 2
- 102100023037 Wee1-like protein kinase Human genes 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000004907 gland Anatomy 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 210000000626 ureter Anatomy 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539734P | 2017-08-01 | 2017-08-01 | |
| US62/539,734 | 2017-08-01 | ||
| PCT/US2018/044580 WO2019028008A1 (en) | 2017-08-01 | 2018-07-31 | 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE ANALOGUES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2020105058A true RU2020105058A (ru) | 2021-09-02 |
| RU2020105058A3 RU2020105058A3 (enExample) | 2021-11-17 |
Family
ID=65233095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020105058A RU2020105058A (ru) | 2017-08-01 | 2018-07-31 | Аналоги 1,2-дигидро-3н-пиразоло[3,4-d]пиримидин-3-она |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11124518B2 (enExample) |
| EP (1) | EP3661918B1 (enExample) |
| JP (1) | JP7203816B2 (enExample) |
| KR (1) | KR20200034781A (enExample) |
| CN (1) | CN111094253B (enExample) |
| AR (1) | AR112774A1 (enExample) |
| AU (1) | AU2018312448B2 (enExample) |
| BR (1) | BR112020002104A2 (enExample) |
| CA (1) | CA3071405A1 (enExample) |
| ES (1) | ES2980537T3 (enExample) |
| IL (1) | IL272262A (enExample) |
| MX (1) | MX2020001235A (enExample) |
| RU (1) | RU2020105058A (enExample) |
| SG (1) | SG11202000789WA (enExample) |
| TW (1) | TW201910335A (enExample) |
| WO (1) | WO2019028008A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3694861A4 (en) * | 2017-10-09 | 2021-05-19 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| AU2018347307A1 (en) | 2017-10-09 | 2020-04-23 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| AU2019227823B2 (en) * | 2018-02-28 | 2024-12-12 | The Regents Of The University Of Colorado, A Body Corporate | WEE1 kinase inhibitors and methods of treating cancer using the same |
| KR102810102B1 (ko) * | 2018-03-09 | 2025-05-21 | 리커리엄 아이피 홀딩스, 엘엘씨 | 치환된 1,2-다이하이드로-3H-피라졸로[3,4-d]피리미딘-3-온 |
| CN110872296B (zh) * | 2018-08-31 | 2023-05-23 | 上海弘翊生物科技有限公司 | 一种二氢异吲哚-1H-吡唑并[3,4-d]嘧啶酮化合物、其制备方法和应用 |
| EP3952876A4 (en) * | 2019-04-09 | 2023-04-19 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| EP3952877A4 (en) * | 2019-04-09 | 2022-12-14 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| US20220220115A1 (en) * | 2019-04-09 | 2022-07-14 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| WO2020210320A1 (en) * | 2019-04-11 | 2020-10-15 | Recurium Ip Holdings, Llc | Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| CN112142748B (zh) * | 2019-06-28 | 2023-07-04 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
| CA3145344A1 (en) | 2019-06-28 | 2020-12-30 | Shanghai Pharmaceuticals Holding Co., Ltd. | Pyrazolopyrimidine compound, preparation method for same and applications thereof |
| CN112442049A (zh) * | 2019-09-03 | 2021-03-05 | 微境生物医药科技(上海)有限公司 | 作为Wee1抑制剂的嘧啶衍生物 |
| CN114829343A (zh) | 2019-11-15 | 2022-07-29 | 里科瑞尔姆Ip控股有限责任公司 | 叔醇的手性合成 |
| BR112022012281A2 (pt) * | 2019-12-20 | 2022-08-30 | Recurium Ip Holdings Llc | Combinações |
| AU2021271844A1 (en) * | 2020-05-15 | 2022-12-08 | Recurium Ip Holdings, Llc | Mono- and combination therapies |
| CN115698006B (zh) * | 2020-06-17 | 2024-03-29 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的吡唑并[3，4-d]嘧啶-3-酮衍生物 |
| CN114805357B (zh) * | 2021-01-21 | 2023-12-19 | 四川大学 | 一种靶向setdb1-ttd的小分子抑制剂及其制药用途 |
| CA3214894A1 (en) * | 2021-04-30 | 2022-11-03 | Yuli Xie | Fused ring compound as wee-1 inhibitor, and preparation method therefor and use thereof |
| WO2023016417A1 (zh) * | 2021-08-11 | 2023-02-16 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物 |
| CN117940430B (zh) * | 2021-09-22 | 2025-10-31 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物 |
| WO2023166080A1 (en) | 2022-03-01 | 2023-09-07 | Step Pharma S.A.S. | Combination treatments comprising a ctps1 inhibitor and a wee1 inhibitor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006074985A1 (en) * | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
| PE20080695A1 (es) * | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
| WO2009054332A1 (ja) * | 2007-10-23 | 2009-04-30 | Banyu Pharmaceutical Co., Ltd. | ピリドン置換ジヒドロピラゾロピリミジノン誘導体 |
| ES2644964T3 (es) * | 2012-09-10 | 2017-12-01 | Principia Biopharma Inc. | Compuestos pirazolopirimidínicos comos inhibidores de cinasas |
| GB201612092D0 (en) * | 2016-07-12 | 2016-08-24 | Almac Discovery Ltd | Pharmaceutical compounds |
-
2018
- 2018-07-31 CN CN201880059242.4A patent/CN111094253B/zh active Active
- 2018-07-31 BR BR112020002104-0A patent/BR112020002104A2/pt not_active Application Discontinuation
- 2018-07-31 MX MX2020001235A patent/MX2020001235A/es unknown
- 2018-07-31 AU AU2018312448A patent/AU2018312448B2/en not_active Ceased
- 2018-07-31 KR KR1020207005636A patent/KR20200034781A/ko not_active Ceased
- 2018-07-31 EP EP18842344.6A patent/EP3661918B1/en active Active
- 2018-07-31 SG SG11202000789WA patent/SG11202000789WA/en unknown
- 2018-07-31 TW TW107126578A patent/TW201910335A/zh unknown
- 2018-07-31 ES ES18842344T patent/ES2980537T3/es active Active
- 2018-07-31 RU RU2020105058A patent/RU2020105058A/ru unknown
- 2018-07-31 US US16/635,348 patent/US11124518B2/en active Active
- 2018-07-31 WO PCT/US2018/044580 patent/WO2019028008A1/en not_active Ceased
- 2018-07-31 CA CA3071405A patent/CA3071405A1/en active Pending
- 2018-07-31 JP JP2020505356A patent/JP7203816B2/ja active Active
- 2018-08-01 AR ARP180102185A patent/AR112774A1/es not_active Application Discontinuation
-
2020
- 2020-01-26 IL IL272262A patent/IL272262A/en unknown
-
2021
- 2021-06-15 US US17/304,154 patent/US20210317124A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020529993A (ja) | 2020-10-15 |
| US11124518B2 (en) | 2021-09-21 |
| KR20200034781A (ko) | 2020-03-31 |
| SG11202000789WA (en) | 2020-02-27 |
| BR112020002104A2 (pt) | 2020-08-04 |
| CN111094253B (zh) | 2023-08-29 |
| ES2980537T3 (es) | 2024-10-01 |
| US20210317124A1 (en) | 2021-10-14 |
| AU2018312448B2 (en) | 2022-09-15 |
| WO2019028008A1 (en) | 2019-02-07 |
| EP3661918C0 (en) | 2024-05-08 |
| CN111094253A (zh) | 2020-05-01 |
| RU2020105058A3 (enExample) | 2021-11-17 |
| CA3071405A1 (en) | 2019-02-07 |
| TW201910335A (zh) | 2019-03-16 |
| US20200157112A1 (en) | 2020-05-21 |
| EP3661918B1 (en) | 2024-05-08 |
| JP7203816B2 (ja) | 2023-01-13 |
| AU2018312448A1 (en) | 2020-02-13 |
| IL272262A (en) | 2020-03-31 |
| AR112774A1 (es) | 2019-12-11 |
| EP3661918A4 (en) | 2021-05-12 |
| EP3661918A1 (en) | 2020-06-10 |
| MX2020001235A (es) | 2020-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020105058A (ru) | Аналоги 1,2-дигидро-3н-пиразоло[3,4-d]пиримидин-3-она | |
| JP2020529993A5 (enExample) | ||
| RU2013128448A (ru) | Производные триазола в качестве ингибиторов сигнального пути wnt | |
| AR108325A1 (es) | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas | |
| MX338504B (es) | Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso. | |
| RU2010106878A (ru) | Комбинация антимитотического агента и ингибитора аврора киназы как средство для лечения рака | |
| RU2009149210A (ru) | Ингибиторы днк-зависимой протеинкиназы (днк-пк) | |
| RU2014145121A (ru) | Пиримидиновые соединения для лечения злокачественной опухоли | |
| RU2016118753A (ru) | Производные пиридилкетона, способ их получения и их фармацевтическое применение | |
| RU2014147105A (ru) | 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения | |
| EA201290957A1 (ru) | Пиразол-4-илгетероциклилкарбоксамидные соединения и способы их применения | |
| TW200801012A (en) | Phosphoinositide 3-kinase inhibitor compounds and methods of use | |
| RU2014115847A (ru) | Пирролопиримидиновые соединения для лечения злокачественной опухоли | |
| MX340013B (es) | Compuestos de benzoxazepina selectivos para fosfatidilinositol 3-cinasa (pi3k) p110 delta y metodos de uso. | |
| WO2007136858A3 (en) | Small molecule inhibitors of stat3 with anti-tumor activity | |
| RU2013109143A (ru) | Бензимидазол- и азабензимидазолсодержащие соединения, которые ингибируют киназу анапластической лимфомы | |
| RU2015107733A (ru) | Терапевтические средства на основе производных диглицилиловых простых эфиров и способы их применения | |
| UA124001C2 (uk) | Інгібітори протеїнкіназ, спосіб їх отримання і медичне застосування | |
| JP2013199483A5 (enExample) | ||
| JP2021508318A (ja) | チューブリン阻害剤 | |
| CN103664904A (zh) | 一种γ-分泌酶抑制剂及其用途 | |
| RU2013150102A (ru) | Ингибиторы parp для лечения cipn | |
| RU2019143854A (ru) | Лечебное соединение | |
| EA200800516A1 (ru) | Производные n-фенил-2-пиримидинамина и процесс их получения | |
| RU2013131241A (ru) | Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака |